OJOG  Vol.3 No.2 , March 2013
Interferon-induced progression of autoimmune thyroiditis with enlarged thyroid glands in gynecological patient: A case report and literature review
ABSTRACT

A case report presents a progression of autoimmune thyroiditis with an abnormal enlargement of the thyroid glands and increased thyreotropin hormone concentration-associated with interferon treatment in human papillomavirus infected patient with the autoimmune thyroiditis and a daily L-thyroxin hormone replacement therapy background. Observation was supplemented with a brief review of literature and discussion. On the basis of this observation and a brief review of literature authors suggested that the potential adverse effects of interferon therapy are overbalanced than its benefits for gynecological patients, therefore any interferon treatment should be recommended with strict indications as well as after screening of conditions and functions of thyroid glands and other interferon target organs to avoid interferon treatment side effects. Practitioners especially gynecologists should inform their patients about pleiotropic interferon effects and its high frequent and wide range side effects before to start such kind of treatment.


Cite this paper
Mynbaev, O. , Eliseeva, M. , Chernov, A. , Kosmas, I. , Tinelli, A. , Radzinsky, V. and Tsarev, V. (2013) Interferon-induced progression of autoimmune thyroiditis with enlarged thyroid glands in gynecological patient: A case report and literature review. Open Journal of Obstetrics and Gynecology, 3, 257-261. doi: 10.4236/ojog.2013.32048.
References
[1]   Rozati, S., Naef, L., Levesque, M.P., French, L.E. and Dummer, R. (2012) Real-life experience with pegylated interferon and conventional interferon in adjuvant melanoma therapy. Journal of Immunotherapy, 36, 52-56.

[2]   Inman, B.A., Harrison, M.R. and George, D.J. (2012) Novel immunotherapeutic strategies in development for renal cell carcinoma. European Urology, in Press. doi:10.1016/j.eururo.2012.10.006

[3]   Coppin, C., Porzsolt, F., Awa, A., Kumpf, J., Coldman, A. and Wilt, T. (25 January 2005) Immunotherapy for advanced renal cell cancer. Cochrane Database of Systematic Reviews, Article ID: CD001425.

[4]   Ruiz-Delgado, G.J., Tarin-Arzaga, L.C., Alarcon-Urdaneta, C., Calderon-Garcia, J., Gomez-Almaguer, D. and Ruiz-Arguelles, G.J. (2012) Treatment of hairy cell leukemia: Long-term results in a developing country. Hematology, 17, 140-143. doi:10.1179/102453312X13376952196331

[5]   Regnier-Rosencher, E., Guillot, B. and Dupin, N. (2012) Treatments for classic Kaposi sarcoma: A systematic review of the literature. Journal of the American Academy of Dermatology, 68, 313-331.

[6]   Chen, Y.S., Yi, W. and Jiang, K. (2012) Effects of antiviral nucleotide/nucleoside analogues and interferon on hepatitis B virus-related liver cirrhosis: A meta-analysis. Zhonghua Gan Zang Bing Za Zhi, 20, 811-816.

[7]   Chayama, K., Hayes, C.N., Ohishi, W. and Kawakami, Y. (2012) Treatment of chronic hepatitis C virus infection in Japan: Update on therapy and guidelines. Journal of Gastroenterology, 48, 1-12.

[8]   Enudi, W. and Udolu, O.J. (2009) Neuropsychiatric complications associated with interferon-alpha-2b treatment of malignant melanoma. African Journal of Psychiatry (Johannesbg), 12, 227-228.

[9]   McNutt, M.D., Liu, S., Manatunga, A., Royster, E.B., Raison, C.L., Woolwine, B.J., Demetrashvili, M.F., Miller, A.H. and Musselman, D.L. (2012) Neurobehavioral effects of interferon-alpha in patients with hepatitis-C: Symptom dimensions and responsiveness to paroxetine. Neuropsychopharmacology, 37, 1444-1454. doi:10.1038/npp.2011.330

[10]   Malaguarnera, M., Vicari, E., Calogero, A., Cammalleri, L., Di, F.I., Gargante, M.P., Pennisi, G., Risino, C., Ranno, S. and Rampello, L. (2008) Sexual dysfunction in chronic hepatitis C virus patients treated with interferon alpha and ribavirin. Journal of Interferon & Cytokine Research, 28, 603-609. doi:10.1089/jir.2008.0021

[11]   Dove, L.M., Rosen, R.C., Ramcharran, D., Wahed, A.S., Belle, S.H., Brown, R.S. and Hoofnagle, J.H. (2009) Decline in male sexual desire, function, and satisfaction during and after antiviral therapy for chronic hepatitis C. Gastroenterology, 137, 873-884.

[12]   Argiris, A., Agarwala, S.S., Karamouzis, M.V., Burmeister, L.A. and Carty, S.E. (2008) A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer. Invest New Drugs, 26, 183-188. doi:10.1007/s10637-007-9091-2

[13]   Kose, S., Gozaydin, A., Akkoclu, G. and Ece, G. (2012) Chronic hepatitis B with type I diabetes mellitus and autoimmune thyroiditis development during interferon alpha therapy. The Journal of Infection in Developing Countries, 6, 364-368.

[14]   Andrade, L.J., Atta, A.M., Atta, M.L., Mangabeira, C.N. and Parana, R. (2011) Thyroid disorders in patients with chronic hepatitis C using interferon-alpha and ribavirin therapy. Brazilian Journal of Infectious Diseases, 15, 377-381. doi:10.1590/S1413-86702011000400013

[15]   Menconi, F., Hasham, A. and Tomer, Y. (2011) Environmental triggers of thyroiditis: hepatitis C and interferonalpha. Journal of Endocrinological Investigation, 34, 78-84

[16]   Fentiman, I.S., Thomas, B.S., Balkwill, F.R., Rubens, R.D. and Hayward, J.L. (1985) Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet, 1, 1166.

[17]   Oppenheim, Y., Kim, G., Ban, Y., Unger, P., Concepcion, E., Ando, T. and Tomer, Y. (2003) The effects of alpha interferon on the development of autoimmune thyroiditis in the NOD H2h4 mouse. Clinical and Developmental Immunology, 10, 161-165. doi:10.1080/10446670310001642177

[18]   Tomer, Y. and Menconi, F. (2009) Interferon induced thyroiditis. Best Practice & Research: Clinical Endocrinology & Metabolism, 23, 703-712. doi:10.1016/j.beem.2009.07.004

[19]   Buck, H.W., Jr. (2010) Genital warts. Clinical Evidence, 2010, PMC3217761.

[20]   Yang, J., Pu, Y.G., Zeng, Z.M., Yu, Z.J., Huang, N. and Deng, Q.W. (2009) Interferon for the treatment of genital warts: A systematic review. BMC Infectious Diseases, 9, 156. doi:10.1186/1471-2334-9-156

[21]   Mynbaev, O.A. and Eliseeva, M.Y. (2011) The scoring scale of researches’ cogency devoted to efficacy of immunomodulators from the position of evidence-based medicine. Siberian Journal of Oncology, N6, 70-73. (Rus.)

[22]   Mynbaev, O.A., Eliseeva, M.Y. and Chernov, A.V. (2011) Lapsus creativus or sciolistic daydreaming (Manilovshina). Z Turbotoyu pro Zhinku, 3, 32-34. (Rus.)

[23]   Ward, D.L. and Bing-You, R.G. (2001) Autoimmune thyroid dysfunction induced by interferon-alpha treatment for chronic hepatitis C: Screening and monitoring recommendations. Endocrine Practice, 7, 52-58.

[24]   Caraccio, N., Giannini, R., Cuccato, S., Faviana, P., Berti, P., Galleri, D., Dardano, A., Basolo, F., Ferrannini, E. and Monzani, F. (2005) Type I interferons modulate the expression of thyroid peroxidase, sodium/iodide symporter, and thyroglobulin genes in primary human thyrocyte cultures. The Journal of Clinical Endocrinology & Metabolism, 90, 1156-1162. doi:10.1210/jc.2004-1173

[25]   Caraccio, N., Cuccato, S., Pratesi, F., Dardano, A., Ursino, S., Chimenti, D., Boldrini, L., Materazzi, G., Migliorini, P. and Monzani, F. (2009) Effect of type I interferon(s) on cell viability and apoptosis in primary human thyrocyte cultures. Thyroid, 19, 149-155. doi:10.1089/thy.2008.0290

[26]   Akeno, N., Smith, E.P., Stefan, M., Huber, A.K., Zhang, W., Keddache, M. and omer, Y. (2011) IFN-alpha mediates the development of autoimmunity both by direct tissue toxicity and through immune cell recruitment mechanisms. The Journal of Immunology, 186, 4693-4706. doi:10.4049/jimmunol.1002631

[27]   Simin, M., Brok, J., Stimac, D., Gluud, C. and Gluud, L.L. (2007) Cochrane systematic review: Pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. Alimentary Pharmacology & Therapeutics, 25, 1153-1162. doi:10.1111/j.1365-2036.2007.03294.x

[28]   Minami, T., Kishikawa, T., Sato, M., Tateishi, R., Yoshida, H. and Koike, K. (2012) Meta-analysis: Mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C. Journal of Gastroenterology, 48, 254-268.

[29]   Tran, H.A., Jones, T.L., Ianna, E.A., Foy, A. and Reeves, G.E. (27 November 2012) Thyroid disease in chronic hepatitis C infection treated with combination interferonalpha and ribavirin: Management strategies and future perspective. Endocrine Practice, 1-33.

 
 
Top